DC-CIK细胞联合替吉奥治疗非小细胞肺癌的疗效观察

目的 观察树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)联合替吉奥治疗非小细胞肺癌的临床疗效.方法 76例非小细胞肺癌(NSCLC)患者随机分为两组(n=38),对照组单用替吉奥治疗,观察组在对照组治疗的基础上加以DC-CIK细胞治疗.采集观察组患者的外周静脉血进行DC细胞培养和CIK细胞培养.于治疗前与治疗7d后用流式细胞仪检测两组患者外周血中CD4+/CD8+、CD44+NK细胞的表达情况, 以及检测两组患者的白细胞数、血小板数,并观察两组患者的非小细胞肺癌症状.结果 观察组治疗后的外周血中CD4+/CD8+、CD4圾NK细胞百分比分别为(1.65±1.03)、(34.56±8.90)和(18.68±7.98),均显著高于对照组的(1.32±0.70)、(29.07±7.15)和(15.28±8.23),差异均具有统计学意义(均P＜0.05);观察组治疗后CD8+细胞百分比(25.56±8.90)与对照组(26.64±6.77)差异无统计学意义(P＞0.05),呕吐、白细胞降低、血小板降低的患者少于对照组,差异均具有统计学意义(均P＜0.05);观察组患者1年生存率为52.63％明显高于对照组患者的42.11％,差异具有统计学意义(P＜0.05).结论 DC-CIK细胞联合替吉奥治疗非小细胞肺癌能有效提高临床疗效,延长患者的生存时间,是一种安全、有效的治疗方案.

Therapeutic effect of DC-CIK cells combined with S-1 in the treatment of non-small-cell lung cancer

Objective To observe the clinical effect of DC-CIK cells combined with S-1 in the treatment of non-small-cell lung cancer.Methods 76 patients with non-small-cell lung cancer were randomly divided into the observation group and the control group on average.The control group was treated with S-1,and the observation group was treated with DC-CIK cells combined with S-1.For the observation group,the peripheral venous blood was collected before the treatment for DC cells and CIK cells cultivation.The expression of CD4+/CD8+,CD4+ and NK cells in the peripheral blood of the two groups was detected by flow cytometry before the treatment and after one week of the treatments.Besides,the number of white blood cells and platelet count were also measured and the symptoms of non-small-cell lung cancer were observed.Results The percentage of CD4+/CD8+,CD4+ and NK cells in the peripheral blood of the observation group after the treatment was (1.65±1.03),(34.56±8.90) and (18.68±7.98),respectively,which was significantly higher than (1.32±0.70),(29.07±7.15) and (15.28±8.23) in the control group (all P＜0.05).There was no significant difference in the percentage of CD8+ cells between the observation group (25.56± 8.90) and the control group (26.64±6.77) (P＞0.05).The vomiting,leukopenia and thrombocytopenia in the observation group were less than those in the control group (all P＜0.05).The one-year survival rate was 52.63％ in the observation group which was significant higher than 42.11％ in the control group (P＜0.05).Conclusions DC-CIK cells combined with S-1 is a safe and effective treatment for non-small-cell lung cancer,which can effectively improve the clinical efficacy and prolong the survival time of patients.